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OBJECTIVE— To examine the relationship between iron status, hereditary hemochromato-
sis (HFE) gene mutations, and clinical features and outcomes of type 2 diabetes in a well-
characterized representative sample of community-based patients.
RESEARCH DESIGNANDMETHODS— HFE genotype data were available for 1,245
type 2 diabetic patients from the longitudinal observational Fremantle Diabetes Study (FDS),
representing 96.2% of the total FDS type 2 diabetes cohort. Data were collected at recruitment
between 1993 and 1996 and annually until the end of June 2001. Hospitalization and mortality
data were available until the end of June 2006. The presence of the C282Y HFE mutation was
determined in all subjects and H63D in C282Y heterozygotes. Fasting serum iron, transferrin,
and ferritin were measured in all C282Y homozygotes and C282Y/H63D heterozygotes and in
286 randomly selected wild-type subjects. Multiple logistic regression analysis was performed to
determine independent baseline associates of prevalent complications (myocardial infarction,
cerebrovascular disease, retinopathy, neuropathy, and nephropathy), as was Cox proportional
hazards modeling to determine predictors of incident complications and mortality.
RESULTS— Although there were expected positive associations between HFE gene muta-
tions and serum iron and transferrin saturation, there were no independent positive associations
between HFE gene status and either microvascular or macrovascular complications in cross-
sectional and longitudinal analyses. HFE gene status did not independently predict cardiac or
all-cause mortality. Measures of iron metabolism including serum ferritin were not associated
with combined microvascular or macrovascular end points.
CONCLUSIONS— Directed screening for iron overload and/or HFE mutations appears
unwarranted in patients with type 2 diabetes.
Diabetes Care 31:1795–1801, 2008
A lthough early reports suggested thathemochromatosis protects againstthe chronic complications of diabe-
tes (1), recent studies have identified ad-
verse metabolic and vascular effects that
could be associated with iron overload
(2–11). Serum ferritin correlates posi-
tively with insulin resistance and glycated
hemoglobin (2) and has been suggested to
be an additional component of the meta-
bolic syndrome (3). Hyperglycemia, and
other effects of excess tissue iron includ-
ing oxidant stress, angiogenesis, and fi-
brosis (4 – 6), could promote the
development of complications such as ne-
phropathy (7,8). The C282Y and H63D
variants of the hemochromatosis (HFE)
gene product are important determinants
of iron storage. HFE-related hemochro-
matosis is considered to include C282Y
homozygous and compound C282Y/
H63D heterozygous genotypes (9). H63D
and C282Y have been reported to be in-
dependent risk factors for diabetic ne-
phropathy (10) and proli ferat ive
retinopathy (11), respectively.
Because most published studies have
been small-scale and cross-sectional, with
a restricted number of potentially explan-
atory variables, there is a need for detailed
large-scale longitudinal studies examin-
ing the relationship between iron metab-
olism, HFE mutations, and the clinical
features and complications of diabetes
(4). Such studies are essential before di-
rected screening for iron overload can be
recommended in diabetic patients (12).
We have, therefore, analyzed data from
the observational Fremantle Diabetes
Study (FDS) to assess the effects of iron
status and HFE mutations on the charac-
teristics and outcome of type 2 diabetes.
RESEARCH DESIGN AND
METHODS—The FDS took place in a
postal code–defined urban community of
120,097 people in the state of Western
Australia. Descriptions of recruitment
and details of nonrecruited patients have
been published (13). Of 2,258 diabetic
patients identified between 1993 and
1996, 1,426 (63%) entered the FDS and
1,294 had type 2 diabetes based on age at
diagnosis, history of insulin treatment,
adiposity, and other features including is-
let autoantibody status if required (13).
Eligible patients who were not recruited
were a mean of 1.4 years older than par-
ticipants, but their sex distribution and
the distributions of diabetes types and
treatment modalities were similar (13,14).
The FDS protocol was approved by the
Fremantle Hospital Human Research Ethics
Committee, and all subjects gave informed
consent.
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Clinical assessment
At baseline and annual reviews up to No-
vember 2001, a questionnaire was com-
pleted, a physical examination was
performed, and fasting biochemical tests
were carried out in a single laboratory us-
ing standard methods (13). Assessments
in a small minority of patients (3%)
with self-reported acute intercurrent ill-
ness or with clinical signs of an acute in-
fection were deferred until after recovery.
Ethnic background was assessed as north-
ern European (principally Anglo-Celts),
southern European, Asian, African, Ab-
original, or other (13). Identification of
the metabolic syndrome was by the defi-
nitions of the World Health Organization,
the National Cholesterol Education Pro-
gram’s Adult Treatment Panel III, and the
International Diabetes Federation Con-
sensus Group (14).
Complications were identified using
standard criteria (15). Peripheral neurop-
athy was defined as a score2 of 8 on the
Michigan Neuropathy Screening Instru-
ment clinical portion. Retinopathy was
taken as any grade detected by direct/
indirect ophthalmoscopy and/or ophthal-
mologist assessment. Self-reported
stroke/transient ischemic attack was
amalgamated with prior hospitalizations
to define baseline cerebrovascular disease
(CVD) status. Patients were classified as
having coronary heart disease (CHD) if
there was a self-reported history of/
hospitalization for myocardial infarction
(MI), angina, revascularization, and/or def-
inite MI on a Minnesota-coded electrocar-
diogram. Peripheral arterial disease was
considered present when the ankle-to-
brachial index was 0.90. Nephropathy
was defined as a first-morning urinary albu-
min-to-creatinine ratio3.0 mg/mmol.
Mortality and hospital morbidity
data
A government register records all hospi-
talizations in Western Australia and, with
the death register, is part of the Western
Australia Data Linkage System (WADLS)
(16). The WADLS was linked to the FDS
database to provide morbidity/mortality
data from the beginning of the study until
the end of June 2006. Causes of death
were classified independently by two in-
vestigators (T.M.E.D. and D.G.B.) as car-
diac/other (15), with consensus if
required. Hospitalizations were catego-
rized using International Classification of
Diseases 9-CM and 10-AM codes (17).
Laboratory measurements
HFE gene mutations were determined in
buffy-coat DNA by PCR amplification
using published primers (18), followed
by restriction enzyme cleavage and
analysis on a 3% agarose gel. All sub-
jects were assessed for C282Y using the
unique RsaI digestion site. Because it is
not clinically significant in the absence
of C282Y (9,19), H63D was determined
only in C282Y heterozygotes using the
unique MboI digestion site. We divided
subjects into 1) wild types, 2) C282Y/
wild-type heterozygotes, 3) compound
C282Y/H63D heterozygotes, and 4)
C282Y homozygotes.
Fasting serum iron, transferrin, and
ferritin were measured in available sam-
ples from C282Y homozygotes and het-
erozygotes and in 286 randomly selected
wild-type subjects, using established as-
says (18). All sera were stored at 80°C
until analysis. Serum iron was measured,
after separation from transferrin in an
acidic guanidinium chloride solution and
reduction with ascorbic acid, from the ab-
sorbance of the colored complex formed
with ferroZine (Hitachi 917 analyzer;
Boehringer Mannheim, Sydney, Austra-
lia). Serum transferrin was determined by
rate immunoturbidity (Hitachi 917 ana-
lyzer). Transferrin saturation was calcu-
lated as [serum iron/(2  serum
transferrin)]  100. Serum ferritin was
measured using a two-site chemilumino-
metric immunoassay (ACS-180; Ciba,
Corning, MA).
Data analysis
Pancreatic -cell function (%B) and tis-
sue insulin sensitivity (%S) were esti-
mated from fasting serum glucose and
insulin using homoeostasis model as-
sessment (20). Statistical analysis was
performed using SPSS for Windows
(version 14.0) and parametric or non-
parametric tests as appropriate. Multi-
ple linear regression analysis was used
to examine relationships between in-
dexes of iron status and %B and %S.
Multiple logistic regression (forward
conditional entry at P  0.05, removal
at P  0.10) was performed to deter-
mine independent associates of preva-
lent baseline complications. Because of
limited numbers, C282Y homo- and
heterozygotes were pooled for compar-
ison with wild-type subjects. Survival
curves for all-cause mortality, cardiac
death, or first occurrence of complica-
tions defined by HFE status were con-
structed using Kaplan-Meier estimates
and compared by a log-rank test. Cox pro-
portional hazards modeling (forward con-
ditional entry at P  0.05, removal at P 
0.05) was used to determine independent
predictors of these events, with the validity
of the proportional hazards assumption as-
sessed from ln[ln(survival)] curves and
time-dependent covariates. All clinically
plausible univariate variables with P 0.20
were considered for entry.
RESULTS
Baseline patient characteristics
The characteristics of the 1,245 type 2 di-
abetic patients with complete HFE geno-
type data (96.2% of the total type 2
diabetes cohort) are summarized in Table
1. Major mutations were most frequent
among the 786 patients of Anglo-Celt eth-
nicity and least in the 229 Southern Eu-
ropeans. The significant relationship
between education and HFE genotype re-
flects the fact that Anglo-Celts were more
likely to have progressed beyond primary
school. Apart from weak associations be-
tween serum lipids and genotype, there
were no significant between-group differ-
ences in a range of demographic, biophys-
ical, and diabetes-specific variables.
Of the eight C282Y homozygotes,
two males were known to have hereditary
hemochromatosis and were managed by
regular venesection. The remaining six
were previously undiagnosed—five were
females aged 47–79 years with a serum
ferritin752 g/l and the other was a 79-
year-old male with a serum ferritin of 2,476
g/l. All except the 79-year-old female were
Anglo-Celt. None of the 14 C282Y/H63D
heterozygotes had been diagnosed previ-
ously with hemochromatosis.
Baseline measures of iron and
glucose metabolism
Valid indexes of iron metabolism were
obtained from 430 patients including 286
who were wild type (Table 2). There were
stepwise increases in serum iron and
transferrin saturation from wild-type pa-
tients to C282Y homozygotes, especially
in males. The same pattern was evident
for serum ferritin, but there was relatively
large within-group variability and no sig-
nificant differences emerged. Although
postmenopausal women had higher se-
rum ferritin concentrations than those
who were premenopausal, there were no
significant differences between HFE ge-
notype groups in either case (P  0.68).
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There were no significant differ-
ences in ln(%B) and ln(%S) by HFE ge-
notype for 386 non–insulin-treated
patients (Table 2). In addition, there
were no significant associations be-
tween serum iron, serum ferritin, or
transferrin saturation and either ln(%B)
or ln(%S) in multiple linear regression
analyses that included ethnicity and
type of oral hypoglycemic therapy as
potential independent variables (P 
0.21).
Prevalent complications and HFE
status
At baseline, there were no significant dif-
ferences in the unadjusted prevalence of
CHD, CVD, neuropathy, or nephropathy
by HFE gene status (wild-type versus any
Table 1—Characteristics of type 2 diabetic FDS patients categorized by HFE mutation status
Wild type
Heterozygous
C282Y
Compound
heterozygous
C282Y/H63D
Homozygous
C282Y/C282Y Trend P
n (%) 1,092 (87.7) 131 (10.5) 14 (1.1) 8 (0.6)
Age (years) 63.8  11.3 65.6  10.4 67.3  7.7 61.1  12.3 0.20
Sex (% male) 48.4 54.2 50.0 37.5 0.57
Ethnic background (%)
Anglo-Celt 60.3 84.0*** 78.6 75.0 0.001
Southern European 20.3 3.1*** 14.3 12.5 NV
Other European 8.9 7.6 7.1 0 NV
Asian 3.8 0 0 0 NV
Mixed/other 5.3 3.8 0 12.5 NV
Aboriginal 1.4 1.5 0 0 NV
Diabetes duration (years) 4.0 1.0–9.0	 4.0 1.5–7.3	 5.4 3.6–11.8	 3.0 0.3–9.0	 0.28
Diabetes treatment (%)
Diet 32.2 35.1 14.3 50.0
Oral agents 55.9 53.4 71.4 37.5 NV
Insulin ( oral agents) 11.9 11.5 14.3 12.5
Fasting plasma glucose (mmol/l) 8.3 6.8–10.7	 8.9 7.1–10.9	 9.7 8.8–11.0	 9.0 6.9–13.0	 0.26
A1C (%) 7.5 6.4–8.8	 7.1 6.3–8.3	 7.6 7.1–8.6	 7.4 6.6–9.3	 0.35
BMI (kg/m²) 29.5  5.4 28.9  5.1 31.6  4.6 36.0  12.1** 0.08
Systolic blood pressure (mmHg) 150  23 151  25 157  17 145  22 0.69
Diastolic blood pressure (mmHg) 80  11 80  12 87  11* 76  11 0.13
Antihypertensive medications (%) 49.5 59.5* 71.4 37.5 0.05
Total serum cholesterol (mmol/l) 5.5  1.1 5.3  0.9 5.7  1.0 4.5  1.0* 0.039
Serum HDL cholesterol (mmol/l) 1.07  0.32 1.02  0.32 1.06  0.30 1.02  0.36 0.42
Serum triglycerides (mmol/l) 1.9 (1.1–3.3) 2.1 (1.3–3.5)* 1.9 (1.1–3.3) 1.6 (1.1–2.3) 0.06
Lipid-lowering medications (%) 10.4 9.2 0 0 NV
Aspirin use 75 mg/day (%) 22.4 19.8 7.1 12.5 NV
Metabolic syndrome (%)
Adult Treatment Panel (ATP) III 85.5 83.7 92.9 62.5 NV
International Diabetes Federation 84.6 86.2 100 87.5 NV
World Health Organization 87.0 93.8 100 87.5 NV
Albumin-to-creatinine ratio (mg/mmol) 3.1 (0.7–13.5) 2.8 (0.7–12.0) 5.7 (1.2–28.1) 1.6 (0.5–4.9) 0.24
Albumin-to-creatinine ratio 3.0 mg/mmol (%) 40.8 40.5 61.5 37.5 0.50
Neuropathy (%) 30.1 35.2 33.3 37.5 0.67
Retinopathy (%) 16.7 9.4 0 25.0 NV
Coronary heart disease (%) 31.0 33.6 35.7 12.5 0.61
Cerebrovascular disease (%) 10.5 6.9 0 0 NV
Peripheral arterial disease (%) 29.1 25.2 46.2 37.5 0.39
Education beyond primary level (%) 72.5 86.7*** 78.6 62.5 0.005
Not able to speak English well (%) 16.5 6.9 14.3 12.5 NV
Married/de facto relationship (%) 66.1 61.8 78.6 62.5 0.57
Exercise in past 2 weeks (%) 72.5 71.8 78.6 50.0 0.51
Smoking (%): Never/Ex-/Current 44.5/40.3/15.2 43.5/42.0/14.5 28.6/64.3/7.1 62.5/25.0/12.5 NV
Alcohol (standard drinks/day) 0 0–0.8	 0 0–0.8	 0 0–0.03	 0 0–0.3	 0.30
Deceased by end of June 2006
All-cause 36.8 36.6 57.1 50.0 0.39
Cardiac 15.0 15.3 0 0 NV
Data are proportions, means SD, medians IQR	, or geometric means (SD range). *P 0.05, **P 0.01, and ***P 0.001 vs. wild type (uncorrected for multiple
comparisons). NV, not valid because of low numbers in some groups.
Davis and Associates
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1797
C282Y mutation; P  0.083), but reti-
nopathy was more common among wild-
type patients (16.7 vs. 7.4%, P 
 0.022).
After adjustment for univariate associates
of each complication in individual multi-
ple logistic regression models, HFE gene
status remained a nonsignificant associate
of CHD, nephropathy, and neuropathy
(P 0.55) and became nonsignificant for
retinopathy (P 
 0.07). Non–wild-type
patients were, however, half as likely to
have CVD as wild-type patients after ad-
justment for age, diabetes duration, and
systolic blood pressure (odds ratio [OR]
0.46 [95% CI 0.22–0.94]; P 
 0.034).
Incident complications, mortality,
and HFE status
The number of complication-free patients
at baseline, the patient-years of follow-up,
and the percentages of patients develop-
ing end points by HFE status are shown in
Table 3. There were no differences be-
tween wild-type and non–wild-type pa-
tients in the time to hospitalization with/
death from MI or stroke or to the
development of peripheral neuropathy,
retinopathy, or nephropathy by log-rank
test. After adjustment for the most parsi-
monious Cox proportional hazards
model (the proportional hazards assump-
tion was valid in all cases), HFE status was
not associated with time to event for any
outcome (Table 3). There was a similar
finding when the small numbers of
C282Y/H63D heterozygotes and C282Y
homozygotes were pooled (n 
 22) and
compared with wild-type patients (data
not shown).
Complications, mortality, and iron
metabolism
Of 423 patients with follow-up data but
without retinopathy, neuropathy, or ne-
phropathy at entry, 139 had baseline
measures of iron metabolism. Of these,
113 (81.3%) had a first microvascular
complication during 425 patient-years
(mean 3.1  2.1 years) of follow-up. In
Cox proportional hazards models, there
was no association between serum iron,
ferritin, or transferrin saturation and the
first occurrence of microangiopathy (P 
0.32). Similarly, there were 1,255 type 2
diabetic patients without prior MI or
stroke at baseline and 418 of these had
measures of iron metabolism. Of these,
129 (30.9%) had a first MI, stroke, or car-
diac/cerebrovascular death during 3,757
patient-years (mean 9.0  3.9 years) of
follow-up. In Cox models, there was no
association between serum iron, ferritin,
or transferrin saturation and the first oc-
currence of this combined macrovascular
end point (P  0.51).
CONCLUSIONS—The present data
do not suggest that iron overload or the
major HFE gene mutations have impor-
tant pathophysiological consequences in
community-based type 2 diabetic pa-
tients. There were the expected associa-
tions between HFE gene status and serum
iron and transferrin saturation but no dif-
ferences in either diabetes treatment or in
Table 2—Serum iron, serum ferritin, transferrin saturation, -cell function, and insulin sensitivity in the subgroups of patients with type 2
diabetes classified according to the major mutations
Wild-type
Heterozygous
C282Y
Compound heterozygous
C282Y/H63D
Homozygous
C282Y/C282Y Trend P
n 286 123 13 8
Serum iron (g/l)
All 16.6  5.4 19.2  7.5* 21.5  5.0* 26.1  14.6 0.001
Male 17.1  5.2 20.7  8.0† 24.6  4.9* 39.6  8.3† 0.001
Female 16.1  5.6 17.3  6.3 18.0  1.4 23.6  14.9* 0.038
Serum ferritin (g/l)
All 111 (41–297) 129 (51–329) 180 (68–478) 136 (22–845) 0.20
Male 139 (55–351) 184 (82–409)‡ 225 (63–804) 263 (35–1,980) 0.09
Female 85 (32–231) 85 (34–212) 139 (90–216) 91 (15–559) 0.70
Transferrin saturation (%)
All 22.9  8.1 27.5  11.2† 34.9  10.4† 56.3  30.7† 0.001
Male 24.3  8.3 30.1  11.8† 41.9  8.6† 71.3  15.1 0.001
Female 21.3  7.6 24.4  9.5‡ 26.8  4.9 47.2  35.5 0.001
n§ 237 107 11 5
-Cell function (%)
All§ 45 (18–108) 43 (16–114) 34 (15–76) 42 (7–271) 0.76
Diet 54 (28–107) (85) 65 (33–129) (41) 32 (24–42) (2) 109 (89–135) (4) NV
Metformin alone 32 (9–114) (24) 40 (22–72) (20) 46 (30–71) (2) — NV
Sulfonylurea alone 47 (21–106) (81) 46 (27–78) (22) 50 (22–113) (4) 41 (1) NV
Combination therapy 36 (17–77) (47) 37 (22–61) (24) 32 (19–52) (3) — NV
Insulin sensitivity (%)
All§ 38 (16–90) 33 (14–77) 39 (20–78) 39 (6–232) 0.36
Diet 39 (20–79) (85) 32 (15–65) (41) 41 (22–77) (2) 21 (16–29) (4) NV
Metformin alone 42 (14–122) (24) 35 (22–55) (20) 46 (30–71) (2) — NV
Sulfonylurea alone 41 (19–89) (81) 35 (20–62) (22) 39 (17–93) (4) 22 (1) NV
Combination therapy 39 (18–84) (47) 30 (17–52) (24) 31 (22–44) (3) — NV
Data are means SD, geometric means (SD range), or means SD (n). *P 0.01 vs. wild type; †P 0.001 vs. wild type (uncorrected for multiple comparisons);
‡P  0.05 vs. wild type; §data are from 362 non–insulin-treated patients. NV, not valid because of low numbers in some groups.
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%B or %S between groups defined by the
HFE mutations relevant to iron overload
and no significant relationship between
%B and %S and any index of iron status.
In addition, despite a higher prevalence of
CVD in wild-type patients at entry, there
were no associations between HFE gene
status and either microvascular or other
macrovascular complications in cross-
sectional and longitudinal analyses, and
incident CVD was similar in patients with
or without HFE mutations. Similarly, HFE
gene status was not an independent pre-
dictor of cardiac or all-cause mortality. In
a subset of patients, indexes of iron status
including serum ferritin were not associ-
ated with combined microvascular or ma-
crovascular end points. These findings
imply that directed screening for iron
overload and/or HFE mutations is unwar-
ranted in type 2 diabetes.
Because serum ferritin reflects inflam-
matory processes as well as total body
iron stores (2) and is influenced by eth-
nicity and adiposity (21,22), the within-
group variability in this parameter was
understandably greater than those of the
other indexes of iron status. Age, sex, and
known hemochromatosis with prior reg-
ular venesection may also have contrib-
uted to the lack of an association between
serum ferritin and HFE status in the
present study. In homozygous C282Y pa-
tients, for example, three of the five fe-
males were not at the stage of accelerated
iron loading seen postmenopause, while
only one of three males (with the highest
serum ferritin) was newly identified with
hemochromatosis. Indeed, the median
serum ferritin concentrations in sub-
groups defined by sex and HFE status
were comfortably below upper reference
limits suggested for adult men (400 g/l)
and postmenopausal women (300 g/l)
(23) and consistent with the Third Na-
tional Health and Nutrition Examination
Survey (NHANES III) data for white dia-
betic women (95% CI 193–211) and men
(99–108) (21). The present data are also
in accord with a twin study showing that
HFE status has minimal effect on serum
ferritin (22).
Serum ferritin is the measure of iron
status most closely associated with insulin
resistance (2,21,24), and it may cluster
with other vascular risk factors (3). Its
possible role in the development of car-
diovascular disease in humans was first
raised 25 years ago (25). However, we
found no association between serum fer-
ritin and %B or %S and no association
between serum ferritin and combined mi-
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crovascular and macrovascular end
points. The numbers of patients in these
analyses were limited, and it is possible
that, in larger cohorts and those with
higher serum ferritin levels, such patho-
physiological relationships exist. Never-
theless, the highest serum ferritin
concentrations are in newly diagnosed di-
abetic patients (2), implying that glycemic
and other vascular risk factor manage-
ment has a normalizing effect. In addi-
tion, recent epidemiologic studies have
not found an independent association be-
tween serum ferritin and cardiovascular
disease (26). The present data are consis-
tent with this finding in the high-risk con-
text of type 2 diabetes.
Because 1) there were only 22 C282Y
homozygous or C282Y/H63D heterozy-
gous patients, 2) significantly elevated se-
rum iron concentrations were observed in
C282Y heterozygotes (without H63D),
and 3) the published observation that the
C282Y allele is associated with microan-
giopathy (11), we pooled all patients with
C282Y for multivariate analysis of com-
plications. Despite contrary evidence
(10,11), the associations between HFE
and angiopathy in our patients paralleled
those for serum ferritin. We had sufficient
numbers of patients to detect ORs of
1.80 and 2.0 for prevalent CHD and
CVD, respectively, in non–wild-type pa-
tients with80% power and to detect an
OR1.60 for incident MI and stroke with
90% power. Thus, if there is an effect of
HFE mutations, and by implication in-
creased tissue iron, on diabetes-related
macroangiopathy, it appears limited.
In a cross-sectional study of 233 se-
lected clinic-based type 2 diabetic pa-
tients (11), the presence of C282Y was
associated with an adjusted OR (95% CI)
for proliferative retinopathy of 6.1 (1.2–
30.5). There were no between-group dif-
ferences by H63D status, and no
biochemical markers of serum iron status
were provided (11). We had few patients
with proliferative retinopathy in our
larger community-based cohort but
found no association between C282Y and
prevalent or incident retinopathy of any
grade. Our patient numbers were suffi-
cient to detect an OR1.80 for prevalent
and 1.60 for incident retinopathy with
80% power, implying that a mildly in-
creased C282Y-associated risk is still pos-
sible. However, the first study to examine
the effect of hemochromatosis on diabetic
microangiopathy found a protective effect
(1). In addition, Peterlin et al. (11) postu-
late iron overload–related retinal damage
to be the mechanism underlying their
findings, but the lack of a relationship be-
tween iron status and microangiopathy in
the present study does not support this
contention.
A second microvascular complication
with a possible association with an HFE
mutation is nephropathy. Moczulski et al.
(10) studied 424 type 2 diabetic clinic
patients with varying degrees of urinary
protein loss and 196 healthy control
subjects. There were no differences in
C282Y prevalence between normoalbu-
minuric and nephropathic patients, but
there was an increased frequency of
H63D mutations in the latter group (OR
1.8 [95% CI 1.2–2.8]) that persisted af-
ter adjustment for A1C and blood pres-
sure (10). No biochemical measures of
iron status were provided (10). Al-
though the authors postulate that their
findings reflect iron-related kidney
damage, the H63D mutation only deter-
mines iron storage when in the H63D/
C282Y heterozygous state (18,19). The
relationship of iron-related tissue dam-
age in hereditary hemochromatosis to
that in hypertransfused patients with
-thalassemia (8) is also uncertain. In
the latter situation, glycemic control but
not serum ferritin is associated with mi-
croalbuminuria, whereas regular des-
ferrioxamine chelation and antioxidant
vitamin supplementation may them-
selves affect nephropathy (8).
Cardiovascular end points are the
major cause of death in type 2 diabetes
(27). Importantly, the present study has
shown no association between HFE mu-
tations and cardiac or all-cause mortality
over a mean follow-up of 10 years. In-
deed, we had sufficient numbers of pa-
tients to detect an OR 1.60 for both
mortality end points in non–wild-type
patients with 90% power. In a similar
long-term study (28), diabetic patients
with hemochromatosis had reduced sur-
vival compared with nondiabetic hemo-
chromatotic patients and subjects from
the normal population. However, with-
out a diabetic nonhemochromatotic
group, this can be interpreted as showing
diabetes-associated reduced life expect-
ancy alone rather than a synergistic effect
of iron overload and diabetes. Alterna-
tively, diabetes may be a relatively late
complication of hereditary hemochroma-
tosis with a consequently minimal effect
on longevity.
The present analyses represent the
largest study of the relationship between
iron metabolism, HFE gene mutations,
and the clinical features and complica-
tions of diabetes, but they have limita-
tions. Because of the observational, “usual
care” nature of the FDS, complete data on
the management of patients with known
hemochromatosis, and its effect on in-
dexes of iron storage and outcome, were
not available. The FDS sample size was
smaller than in other studies such as the
Hemochromatosis and Iron Overload
Screening (HEIRS) study, which had
100,000 participants, but HEIRS was
conducted in the general population and
relied on self-report for diabetes diagno-
sis, and no complication or mortality data
have been reported (21). Interestingly,
the HEIRS study did not show that the
main HFE mutations were associated with
diabetes (21). Indeed, their distribution
in the FDS (87.7% homozygous wild
type, 10.5% heterozygous C282Y/wild
type, 1.1% heterozygous C282Y/H63D,
and 0.6% homozygous C282Y) was sim-
ilar to that in a population-based study in
a large rural Western Australian center
(85.4, 11.9, 2.2, and 0.5%, respectively)
(18). In both cases, the proportions of
heterozygotes were in Hardy-Weinberg
equilibrium, suggesting there was no det-
rimental effect of inheriting C282Y het-
erozygosity on life expectancy. Other
strengths of the present study are the
WADLS capture of both public and pri-
vate hospital admissions in Western Aus-
tralia (16) and the low rates of coding
errors and migration out of Western Aus-
tralia (14).
The present findings, those of studies
such as HEIRS (21), and the results of a
recent systematic review (12) do not pro-
vide evidence that enhanced case finding
strategies for hemochromatosis should
extend to diabetes. Nevertheless, because
the consequences of delayed diagnosis of
hemochromatosis can be significant (28),
patients with weakness, fatigue, joint or
abdominal pain, liver or cardiac disease,
impotence, infertility, or menstrual dis-
turbance that is atypical or unexplained
irrespective of the presence or absence of
diabetes should have biochemical and ge-
netic testing in the same way as individu-
als who have a close blood relative with
hemochromatosis (9).
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